壳聚糖宫颈抗菌膜与重组人干扰素局部治疗宫颈囊肿的疗效和超声学变化对比研究

Comparative Study on Clinical Effect and Ultrasonic Change of Chitosan Cervical Anti- Bacteria Membrane and Recombinant Human Interferon by Local Application for Treating Cervical Cyst

目的对比研究壳聚糖宫颈抗菌膜、重组人干扰素局部用药对宫颈囊肿的临床疗效和超声学变化。方法选取2013年4月至7月收治的宫颈囊肿患者60例,按单发或多发、囊肿发病部位、是否伴宫颈肥胖平均分为壳聚糖宫颈抗菌膜组和重组人干扰素组,比较两组患者临床症状改善和总有效率以及超声学有效率,记录不良反应。结果治疗后两组患者分泌物、瘙痒评分均较治疗前显著下降(P<0.01),灼烧和下腹疼痛评分下降(P<0.05),壳聚糖宫颈抗菌膜组患者分泌物、灼烧评分降低更明显(P<0.05);壳聚糖宫颈抗菌膜组临床总有效率较重组人干扰素组略高,但差异无统计学意义(P>0.05)。壳聚糖宫颈抗菌膜组超声学总有效率比重组人干扰素组略高,但无统计学意义(P>0.05)。治疗过程中,两组均无明显不良反应。结论壳聚糖宫颈抗菌膜局部给药治疗宫颈囊肿,超声学总有效率有高于重组人干扰素,在改善临床症状方面优于重组人干扰素,且安全性高,值得临床推广。

Objective To comparatively investigate the clinical effects and the ultrasonic change of chitosan cervical anti-bacterial membrane and recombinant human interferon by local application for treating cervical cyst in order to provide the reference for their clinical reasonable application. Methods 60 cases of cervical cyst in our hospital from April to July 2013 were selected and divided into the chitosan cervical anti-bacteria membrane group and the recombinant human interferon group according to single or multiple cyst, cyst site and cervical obesity. The improvement and total effective rates of clinical symptoms and the ultrasonic effective rates were compared between the two groups. The adverse reactions were recorded. Resuts The secretion and itching scores after treatment in the two groups were significantly decreased （ P〈0. 01 ） , the ignition and lower abdominal pain scores were reduced （ P〈0. 05 ） . Compared with the recombinant human interferon group, the decrease of the secretion and ignition scores in the chitosan cervical anti-bacteria membrane group was more significant, the difference between them had statistical significance （ P〈0. 05 ） . The total effective rate in the chitosan cervical anti-bacteria membrane group was slightly higher than that in the recombinant human interferon group without statis-tical difference （ P〉0. 05 ） . The ultrasonic effective rate in the chitosan cervical anti-bacteria membrane group was slightly higher than that in the recombinant human interferon group without statistical difference （ P〉0. 05 ） . No obvious adverse reactions occurred during treatment process. Conclusion The chitosan cervical antibacterial film by local application has higher effective rate than the recombi-nant human interferon, is superior to the recombinant human interferon in improving the clinical symptoms, has high safety and deserves to be clinically promoted.